Cytomegalovirus (CMV) infection exerts an enormous effect on human immunity, as it is associated with an immune-impaired response, a variety of chronic diseases, and overall survival in elderly individuals. Levels of anti-CMV antibodies may be associated with the differentiation degree of T cell subsets. Titers are significantly higher in the elderly and positively correlated with specific CD4
T he betaherpesvirus cytomegalovirus (CMV) is a persistent activating virus that primarily resides in the myeloid cell compartment but also spreads to other cell types. Clinically, infection is considered essentially asymptomatic in immunocompetent hosts. However, immunosuppressed individuals may suffer serious consequences as a result of viral reemergence. After infection, the virus establishes lifelong latency within the host and periodically reactivates. Reactivation from latency is a key step in the pathogenesis of the infection and can be detected in response to inflammation, infection, stress, or immunosuppression (1, 2) . Activation of protein kinase C and NF-B by tumor necrosis factor alpha (TNF-␣) and increasing concentrations of cyclic AMP by stress hormones and prostaglandins promote viral reactivation and replication. Reactivation of CMV is more frequent in the elderly, as demonstrated by the direct detection of CMV DNA in the urine. Although reactivation is frequent in the elderly, it is subclinical in nature (3) .
Recently, CMV has been linked to a variety of chronic diseases with an inflammatory component, including cardiovascular diseases, cancer, and cognitive and functional impairment (4-7). The specific mechanisms responsible for these associations have not been fully determined but are likely to have an inflammatory and immune component. Reactivation may result in increased levels of proinflammatory molecules such as interleukin 6 (IL-6), TNF-␣, and C-reactive protein (CRP). In fact, CMV has been associated with a significantly greater risk of all-cause mortality and cardiovascular disease-related mortality in subjects with high CRP levels (8) . Longitudinal aging studies suggest that CMV seropositivity is associated with a cluster of immune parameters, the "immune risk profile" (IRP), which predicts 2-year mortality in a population-based sample of Swedish octogenarians (9) . Moreover, CMV seropositivity is also associated with the phenomenon of immunosenescence, which is characterized by clonal expansion of T cells, mainly CD8
ϩ T cells, with a highly differentiated cell surface phenotype and with the acquisition of new functional features. Moreover, the hallmark of human immunosenescence, irrespective of its association with CMV, is low numbers of naïve T cells, particularly CD8 ϩ T cells, and a corresponding lower diversity of the T cell receptor (TCR) repertoire (10, 11) . This has been proposed as an explanation for much of the decreased ability of the elderly to resist new infections and to respond effectively to reinfection and persistent infections (12) . Indeed, despite the evidence suggesting that CMV induces aging of T lymphocytes, more frequent and/or intensive reactivations in the elderly may be a consequence rather than the cause of immunosenescence. A general result of these alterations is that adaptive immunity seems to weaken with age, whereas innate immunity is maintained or even enhanced. This may be one of several explanations for the commonly reported increase in proinflammatory status in the elderly, which itself is associated with frailty and mortality (13) .
The frequency of CMV seropositivity in the elderly in developed countries is above 80%. In spite of the enormous impact of CMV infection on human immunity, the degree of immunosenescence varies greatly, as is apparent even when only CMV-infected individuals are studied (14) . We postulate that the humoral response to CMV may be a consequence of deleterious changes in the immune system and may be related to other changes induced in the immune response, rather than merely infection per se. To investigate this, we studied the association between anti-CMV antibody titers and various characteristics that define the degree of differentiation and the functional abilities of the T cell fraction.
MATERIALS AND METHODS
Study population. Blood samples for hematological and immunological analyses were obtained from 92 healthy elderly donors (70 females and 22 males) living in the Santa Teresa nursing home (Oviedo, Spain). To ensure that a representative sample of the population was studied, volunteers were not rigorously selected with respect to their health status. Exclusion criteria were conditions with a possible influence on the immune system, such as recent or current infection, inflammation, autoimmune or malignant disease, malnutrition, abnormal laboratory data, and pharmacological interference (steroids, nonsteroidal anti-inflammatory agents, and immunosuppressive drugs). Samples from 70 young healthy controls (24 females and 46 males) were obtained from the Centro de Transfusiones del Principado de Asturias (Oviedo, Spain). Inclusion criteria were a minimum age of 65 years for the elderly group and a maximum age of 50 for the young group. The mean age of the elderly individuals was 85.1 Ϯ 6.3 years (range, 68 to 97 years), and that of the young controls was 38.7 Ϯ 8.4 years (range, 20 to 50 years).
Informed consent was obtained from patients and controls before they participated in the study. The Hospital Universitario Central de Asturias Ethics Committee (Oviedo, Spain) gave ethical approval for the study.
CMV and influenza virus serology. Levels of CMV-specific immunoglobulin G (IgG) antibodies were determined by the enzyme-linked immunosorbent Vir-ELISA anti-CMV IgG assay (Viro-Immun Labor-Diagnostika GmbH, Oberursel, Germany), carried out in accordance with the manufacturer's specifications.
Anti-influenza virus antibodies in serum obtained from elderly individuals were measured by enzyme-linked immunosorbent assay (ELISA) as previously described (15) . The optical density (OD) values of individual samples were compared against a calibration curve comprising the OD values of serial dilutions of the same internal control serum from a healthy vaccinated young person throughout the experiments. Results are expressed as arbitrary units. The antibody titer decreased significantly with time since vaccination, so these values were normalized by adjusting the titer by the time elapsed since immunization.
Hematological analysis and immunological phenotyping. Hematological parameters were determined with a Sysmex XT-2000i analyzer (Sysmex, Hamburg-Norderstedt, Germany). The results of the cytometric studies were analyzed using a FACSCalibur cytometer with CellQuest software (BD Biosciences, San Jose, CA). EDTA-treated peripheral blood was surface stained with the following antibodies (antibody labels are in parentheses): anti-CD8 (phycoerythrin [PE] ϩ CD8 ϩ and CD3 ϩ CD4 ϩ T cells, respectively. Activation studies. CMV-infected cell lysate was prepared by infecting human embryonic lung fibroblasts with the AD169 strain of CMV, and viral titers in the supernatant were determined by standard plaque assays (viral stock, 10 5 PFU/ml). The virus was inactivated by five freezethaw cycles.
Activation of T lymphocytes from heparinized whole blood by anti-CD3 or CMV extract was assessed by surface staining with anti-CD69 (eBioscience). Briefly, heparinized whole blood (250 l) was stimulated with soluble anti-CD3 (10 ng/ml) (eBioscience) or with the CMV supernatant (dilution, 10 4 PFU/ml) in 15-ml conical polypropylene tubes for 18 h at 37°C in an atmosphere of 5% carbon dioxide. After stimulation, cells were stained with anti-CD69 and anti-CD4 monoclonal antibodies.
Proliferation cultures. (16) . Experimental samples were run in duplicate, and the replicate average was used as the sample result.
HLA-DRB1 typing. HLA-DRB1 alleles were typed, in accordance with the manufacturer's protocols, using Lifecodes HLA-SSO typing kits (Tepnel Lifecodes Corporation, Stamford, CT) based on the Luminex Corporation's X-Map technology.
TNF-␣ promoter polymorphism genotyping. Single nucleotide polymorphisms (SNPs) at position Ϫ308 of the TNF-␣ gene were determined by analyzing the melting temperature (T m ) of the probe/target duplex after PCR amplification and hybridization with fluorescently labeled probes matched with one sequence variant (LightCycler; Roche Diagnostics, Mannheim, Germany). The primers used were CCTGCATC CTGTCTGGAAGTTA and CTGCACCTTCTGTCTCGGTTT. The hybridization probes (designed by TIB Molbiol, Berlin, Germany) used were AACCCCGTCCCCATGCCCC-F and LC Red 640-CCAAACCTATTGC CTCCATTTCTTTTGGGGAC.
Cytokine quantification. Cytokine levels were measured in the sera of elderly subjects using X-Map technology with a Milliplex map kit (Millipore, Billerica, MA), according to the manufacturer's specifications. This bead-based analyte detection system was used to quantify human TNF-␣ and IL-15 using the Luminex Corporation's X-Map technology.
Statistical analysis. Groups were compared by the nonparametric Mann-Whitney U and Kruskal-Wallis tests (for non-normally distributed data) or by Student's independent-samples t test (for normally distributed data). Correlations between variables were assessed by the nonparametric Spearman rho test. The 2 test was used to compare dichotomous variables, and multiple linear regression was used to consider variables simultaneously. Analyses were performed using SPSS 15.0 (SPSS Inc., Chicago, IL). Significance was concluded for P values of Ͻ0.05.
RESULTS
CMV seropositivity and antibody titers in young and elderly people. The characteristics of the individuals enrolled in the study are shown in Table 1 . We quantified levels of anti-CMV antibodies in the sera of the 70 young and 92 elderly donors. The frequencies of seropositivity were 52% and 91%, respectively ( VU/ml (IR, 535.5 VU/ml), respectively (Mann-Whitney U test; P Ͻ 0.001) (Fig. 1B) .
Aging was associated not only with the percentage of CMV seropositivity but also with the levels of anti-CMV antibodies.
Correlation between anti-CMV-specific T cells and antibody titer.
To analyze whether individuals with higher anti-CMV antibody titers also have stronger CMV-specific T cell responses, the CD4 ϩ T cell response was measured by stimulating whole-blood cultures with CMV antigens and with anti-CD3. CD69 expression in response to CMV extracts and to anti-CD3 was analyzed in CD4 ϩ T cells. The magnitude of the CD4 ϩ T cell immune responses to CMV was positively correlated with anti-CMV antibody titers in the elderly (Spearman test; rho ϭ 0.490 and P ϭ 0.002) (Fig. 1C) but not in young donors (data not shown). No correlations were found between antibody titers and activation in response to anti-CD3 in CD4 ϩ T cells in elderly subjects (Fig. 1C) . Similarly, when proliferative responses were quantified in PBMC cultures, there was a significant correlation with CD4 ϩ T cell proliferation only in the elderly group in response to CMV (Spearman test; rho ϭ 0.516 and P ϭ 0.01) but not in response to anti-CD3 (Fig. 1D) . No correlations were found between activation or proliferation in CD4
ϩ T cells with anti-CMV antibody titers in young donors (data not shown).
Levels of anti-CMV antibodies and CMV-specific CD4 ϩ T cells were clearly related in elderly individuals.
T cell differentiation subsets and anti-CMV antibody titer. It is widely accepted that the progressive deterioration of the T cell compartment with advancing age is related to CMV seropositivity. T cells can be separated into functionally distinct populations using combinations of cell surface markers such as CD45RA and CCR7. We used these markers to classify the T cells into naïve
, and effector memory RA (EMRA; CD45RA ϩ CCR7 Ϫ ) groups (17) . We wanted to verify 
FIG 1 Frequencies of CMV infection and titers of anti-CMV antibodies in young and elderly subjects and response of CD4
ϩ T cells from elderly subjects to CMV and anti-CD3. Immunoglobulin G levels of CMV-specific antibodies were determined by ELISA and a semiquantitative diagram was used to calculate the CMV titer. (A) Histograms show the percentages of CMV-seropositive (black bars) and CMV-seronegative (white bars) young (n ϭ 70) and elderly (n ϭ 92) subjects. The calculated titers of the patient samples are indicated as VIRO units (VU). Percentages of CMV-infected individuals were compared using the 2 test. (B) Titers of anti-CMV antibodies in infected young (n ϭ 37) and elderly (n ϭ 82) subjects are illustrated in the box plots. Significant group differences, assessed with the Mann-Whitney U test, are indicated. (C and D) CD69 expression and proliferative capacity of CD4 ϩ T cells from elderly subjects in response to CMV in vitro stimulation were analyzed. (C) Correlation between anti-CMV antibody titers and the frequency of CD69 expression in CD4 ϩ subsets from elderly individuals in response to a CMV supernatant (10 4 PFU/ml) (n ϭ 37) and to anti-CD3 (10 ng/ml) (n ϭ 22). Whole blood from CMV-seropositive elderly people was stimulated for 18 h. (D) Proliferative capacity of CD4 ϩ T cell subsets in response to CMV stimulation (n ϭ 28) and to anti-CD3 (n ϭ 27). PBMCs were labeled with CFSE (1.5 M) and cultured in the presence of CMV supernatant or anti-CD3 for 5 days. The percentage of dividing CD4 ϩ T cells is represented. Spearman correlation coefficients and corresponding P values are presented in the upper left-hand corner. n.s., not significant. the association between CMV seropositivity and the degree of differentiation of T cell subsets in young and elderly individuals. First, we compared the distributions of the T cell subpopulations in seropositive and seronegative individuals and found that CMV seropositivity was related to the reduced frequency of undifferentiated subsets, naïve and CM, only in the CD4 ϩ T cells of elderly individuals ( Fig. 2A) . No differences were found in the CD8 ϩ T cells from elderly people. Most CD8 ϩ T cells belonged to the EM and EMRA subsets, which are the final stages of differentiation (data not shown). Moreover, the frequencies of the four populations were similar in young seropositive and seronegative subjects in CD4 ϩ and CD8 ϩ T cells (data not shown). We then calculated the correlation between the anti-CMV antibody titer and the frequency of these T cell subsets. We were unable to demonstrate any associations in young people, but the effect was evident in CD4 ϩ T cells in elderly individuals.
In fact, the frequency of naïve and CM CD4 ϩ T cells showed a significant negative correlation with antibody titers (Spearman test; rho ϭ Ϫ0.443 and P Ͻ 0.001 and rho ϭ Ϫ0.312 and P ϭ 0.005, respectively) (Fig. 2B) . On the other hand, the more differentiated EM subset showed a significant and progressive increase (Spearman test; rho ϭ 0.272 and P ϭ 0.014), and no effect on the proportions of EMRA was found (Fig. 2B) . Again, frequencies of CD8 ϩ T cell subsets were independent of the antibody titers (data not shown).
To examine the differences in the differentiated status of CD4 ϩ T cells from young (n ϭ 25) and elderly (n ϭ 30) CMV-seropositive subjects. The CD4 ϩ population was isolated by magnetic bead separation and the TREC copy number was determined by real-time PCR. Experiments were conducted in duplicate, and the results are presented relative to anti-CMV antibody titers in each subject. Spearman correlation coefficients and corresponding P values are shown in the upper left-hand corner. revealed significant differences in TREC content depending on the levels of anti-CMV antibodies in elderly patients (Spearman test; rho ϭ Ϫ0.444 and P ϭ 0.03) and a nonsignificant trend in young individuals (Fig. 2C) .
In conclusion, both CMV seropositivity and antibody titers influenced the degree of CD4 ϩ T cell differentiation in the elderly, without affecting their CD8 ϩ T cells, and the degree of differentiation in CD4 ϩ and CD8 ϩ T cells of young people. IRP parameters. CMV infection is considered a predictor of survival in very elderly people, but we wanted to evaluate the association of CMV serological status with the other parameters that define the IRP, the CD4/CD8 ratio and the frequency of CD8 ϩ
CD28
null T cells (9, 19) . The CD4/CD8 ratio was slightly lower in seropositive than in seronegative young (Fig. 3A) and elderly (Fig.  3B ) individuals, although neither was statistically significant. However, a significant negative association between anti-CMV antibody titers and the CD4/CD8 ratio was found in elderly people (Spearman test; rho ϭ Ϫ0.235 and P ϭ 0.033) (Fig. 3C) . Conversely, the proportion of CD8 ϩ CD28 null T cells was higher in CMV-seropositive than CMV-seronegative individuals among both the young and elderly subjects (Fig. 3A and B ) (Student's t test; P Ͻ 0.001 and P ϭ 0.045, respectively) but was not correlated with the levels of antibodies (Fig. 3C) .
Since we had demonstrated that differences in the differentiation status of CD4 ϩ T cells are related to CMV infection, we proceeded to analyze the relationship between the virus and the abundance of CD4 ϩ CD28 null T cells. As expected, young and elderly CMV-seropositive people had the highest percentages of CD4 ϩ CD28 null T cells (Fig. 3A and B) (Mann-Whitney U test; P Ͻ 0.001 and P ϭ 0.003, respectively). Furthermore, this subset was significantly increased with higher levels of anti-CMV antibodies in the elderly (Spearman test; rho ϭ 0.348 and P ϭ 0.002), but not in the young (Fig. 3C) .
Anti-CMV antibody titers were related to other parameters of IRP and to CD4 ϩ CD28 null T cells in the elderly but not in young individuals.
Comparisons between young and elderly individuals with similar anti-CMV antibody titers. The lack of correlation between anti-CMV antibodies and other aspects of immunosenescence in the young but not in elderly people may be because the antibody levels in the elderly are much higher than in young individuals. To check whether the profile of cell differentiation found in these groups was due solely to these differences in the antibody titer, we compared the degrees of cell differentiation between young and elderly individuals with similar anti-CMV antibody titers. Individuals were classified into groups defined according to their CMV serological status and the antibody levels in young people, as shown in Fig. 4A (group 0, seronegative; group 1, Յ50th percentile in young individuals; group 2, between 50th and 95th percentiles in young people; group 3, Ͼ95th percentile in young people).
As there were too few young individuals (only three) in group
FIG 3 Relationship between CMV seropositivity and anti-CMV antibody titer with CD4/CD8 ratio and percentages of CD8
ϩ CD28 null and CD4 ϩ CD28 null T cells in young and elderly subjects. CD4/CD8 ratio and percentages of CD8 ϩ CD28 null and CD4 ϩ CD28 null T cells were compared between CMV-seropositive and CMV-seronegative young (A) and elderly (B) subjects. Significant differences are indicated (Student's t test or Mann-Whitney U test). (C) Correlation of anti-CMV antibody titers and CD4/CD8 ratio and percentages of CD8 ϩ CD28 null and CD4 ϩ CD28 null T cells in young (black squares) and elderly (white circles) subjects are represented in the dot plots. Spearman correlation coefficients and corresponding P values are listed on the right-hand side.
3 to carry out any meaningful statistical analysis, they were excluded, so only the elderly individuals in the group were considered. The median anti-CMV antibody titer in each group did not differ between elderly and young people. The mean ages of the elderly individuals were 82.5 Ϯ 8.5 years in group 0, 86 Ϯ 5.5 years in group 1, 85.5 Ϯ 6.3 years in group 2, and 87 Ϯ 5.6 years in group 3. For the young individuals, the mean ages were 38 Ϯ 7.2 years in group 0, 41 Ϯ 10 years in group 1, and 42 Ϯ 9 years in group 2.
Frequencies of CD4 ϩ CD28 null and naïve CD4 ϩ T cells in elderly and young CMV-seronegative individuals (group 0) were very similar, but the differences were progressively greater in the groups with higher antibody levels. This pattern arose mainly because of the variations experienced by these cellular subsets in the elderly groups (Fig. 4B) . On the other hand, in the case of CD8 ϩ T cells, differences were observed between young and elderly individuals in all groups (Fig. 4B ). There were no changes in the differences in the frequency of CD28 null subsets, while differences in naïve subsets diminished in the groups with higher anti-CMV antibody titers. The reason for this in the latter case was the reduction in the number of naïve cells in young people, since their frequency in the elderly was very low in all groups.
The frequency of naïve CD4 ϩ T cells was related to CMV serological status and to anti-CMV antibody titers in elderly people but showed no association in young individuals. We checked whether this effect merely reflects the increase in the number of more differentiated cells, a consequence of which is a reduction in the frequency of naïve cells in the CD4 ϩ T cell compartment. We compared the absolute counts of CD28 null and naïve subsets in CD4 ϩ and CD8 ϩ T cells in the elderly groups (Fig. 4C) . As expected, levels of highly differentiated cells increased significantly in the groups with higher antibody titers, but the differences were not statistically significant when only CMV-seropositive individuals were compared. Surprisingly, a significant reduction in the absolute numbers of CD4 ϩ naïve T cells and an almost complete absence of CD8 ϩ naïve T cells were found in comparisons of all elderly individuals and those who were CMV seropositive. This may be due to some homeostatic mechanisms that limit the generation of new naïve T cells in order to maintain the levels of total T lymphocytes. In fact, in a comparison of the counts of T lymphocytes, those of the three groups of CMV-infected individuals were very similar and higher than those of CMV-seronegative individuals (Fig. 4D) , despite the notable increase in CD28 null cells. We also found a gradual reduction in CD4 ϩ and an increase in CD8 ϩ T cells as the antibody titers rose. null T cells (CD4 ϩ and CD8 ϩ ) in elderly subjects. The Kruskal-Wallis test was used to identify significant differences in frequencies between groups. "*p" indicates a significant difference in comparisons of all groups; "**p" indicates a significant difference when only groups of CMV-seropositive subjects were considered. (D) Absolute counts of CD3 ϩ T cells, distributed into CD4 ϩ (white bars) and CD8 ϩ (black bars), belonging to each group in elderly subjects.
Overall, differences between elderly and young individuals in highly differentiated and naïve CD4 ϩ T cells increased with their anti-CMV antibody titers. The reduction in naïve cells may be a strategy to compensate for the expansion of differentiated cells and to avoid an increase in the total number of T cells.
Genetic features of CMV-infected elderly people. To identify factors favoring CMV reactivation or the poor control of the infection, which may be responsible for the higher antibody titers, we analyzed some genetic characteristics of elderly individuals. Although HLA-DRB1 alleles are associated with increased susceptibility to CMV pathologies in HIV-infected and transplant patients, we were unable to find any associations between levels of anti-CMV antibody and the HLA-DRB1 profile of the elderly donors (data not shown).
Conversely, TNF-␣ is a key mediator in the reactivation of CMV, as well as a differentiation factor associated with the loss of expression of CD28 in T lymphocytes (20) . Mutations in this gene leading to over-or underexpression of the cytokine may be significant in reactivation and the immune response against the virus. We studied the SNP at position Ϫ308 (G/A), which has functional effects on gene transcriptional activity, whereby ϳ308A* is a stronger transcriptional activator than ϳ308G* after in vitro lymphocyte stimulation (21) . Sixty (65.2%) elderly individuals had the GG, 27 (30%) the GA, and 5 (5.5%) the AA genotype. These are frequencies similar to those described for our population. There were no overall differences in the frequency of CMV seropositivity or the anti-CMV antibody titers between the TNF-␣ genotype groups.
We nevertheless tested the levels of TNF-␣ and IL-15, a cytokine that could have a significant role in the proliferation of CD28 null T cells, in the sera of the CMV-seropositive elderly individuals. Again, no association was found between CMV antibody titers and TNF-␣ levels (Fig. 5A) . However, IL-15 levels were positively correlated with antibody titers (Spearman test; rho ϭ 0.532 and P Ͻ 0.001), although they were undetectable in 60.4% of the elderly individuals analyzed (Fig. 5B) .
Our results suggest that anti-CMV antibody titers are not related to either HLA-DRB1 alleles or the Ϫ308 TNF-␣ polymorphism in elderly individuals but are associated with serum IL-15 levels.
Response to vaccination and CMV infection. To determine whether CMV serological status influences the ability to respond to immunization in vivo, we measured the specific antibodies produced against influenza virus vaccination in the four groups of elderly people. The production of specific antibodies to the vaccine diminished gradually and significantly in the groups of CMVseropositive individuals and was related to levels of anti-CMV antibodies (comparisons within all groups, Kruskal-Wallis test; P Ͻ 0.001; within CMV-seropositive groups, P ϭ 0.002) (Fig. 6) . The association between CD8 ϩ CD28 null T cells and the response to vaccination has been demonstrated previously (22) . To verify the influence of CMV seropositivity or the titer of anti-CMV antibodies on the response to vaccination, we performed a multivariate linear regression, including age and levels of CD8 ϩ CD28 null T cells in elderly individuals as predictor variables (Table 2) . It should be noted that in both models, including CMV seropositivity and anti-CMV antibody titer, only CMV status and age emerged as independent predictors of the magnitude of the humoral response to influenza virus vaccination. The influence of levels of CD8 ϩ CD28 null T cells could not be determined in the individuals studied. However, when the titer of anti-CMV antibodies in all elderly individuals (CMV seronegative and CMV seropositive) was included in the model, CD8
ϩ CD28 null T cells were also significantly associated (data not shown).
The in vivo ability to respond to new antigens is influenced by both CMV infection and antibody titers in elderly individuals. 
FIG 6 Response to influenza virus vaccination and its correlation with anti-
CMV antibody (Ab) titer. Anti-influenza virus antibody titers were quantified by ELISA in the sera of elderly individuals after vaccination. The KruskalWallis test was used to compare the influenza antibody titer between CMV groups. "*p" indicates a significant difference in comparisons between all groups; "**p" indicates a significant difference when only groups of CMVseropositive subjects were considered.
DISCUSSION
This study examined whether anti-CMV antibody titers in the serum of young and elderly individuals are related to the phenotypic and functional status of their immune system. Our results suggest a relationship between aging and CMV seropositivity frequency and the levels of anti-CMV antibodies, which are clearly associated with CMV-specific CD4 ϩ T cells in elderly individuals. Moreover, both CMV seropositivity and antibody titers are related to the degree of differentiation of CD4 ϩ T cells and to the IRP parameters of elderly people. Differences between elderly and young individuals in highly differentiated and naïve CD4 ϩ T cells increase depending on their anti-CMV antibody titers, and the reduction in the frequency of naïve cells may be a strategy to compensate for the expansion of differentiated cells and to avoid an increase in the total number of T cells. Our results also suggest that anti-CMV antibody titers are not related to HLA-DRB1 alleles or to the TNF-␣ polymorphism Ϫ308 in elderly individuals but are correlated with serum IL-15 levels. The in vivo ability of elderly individuals to respond to new antigens is also influenced by CMV infection.
The wide-ranging means of transmission of CMV lead to very high seroprevalence, estimated to be between 30% and 90% in developed countries, where it also increases with age (23) . After primary infection, the virus persists for the rest of an individual's life, most commonly in a latent form in a variety of tissues but particularly in precursor cells of the monocytic lineage (24) . Reactivations from latency are likely to occur routinely in healthy virus carriers and chronically in elderly individuals (3) . The relationship between anti-CMV antibodies and the evolution of the infection has been poorly understood. We found that elderly people have higher levels of antibodies than young individuals. One possible explanation for this is that titers of anti-CMV antibodies are indicative of the history of infection, but this hypothesis could be tested by analyzing other characteristics, such as time since infection and the severity or frequency of reactivations. In this way, while individuals with detectable CMV DNA in monocytes have significantly higher percentages of anti-CMV-specific CD8 ϩ T cells, it has not been possible to determine the association with anti-CMV antibody titers. However, the detection of CMV DNA in monocytes could be a marker of current CMV reactivation, and the associated cellular response may reflect the expansion of memory T cells to control the infection (25) . In the present study, we found that activation and proliferation of anti-CMV CD4 ϩ T cells in the elderly was associated with levels of specific antibodies. These results are consistent with a recent paper (26) reporting a correlated increase in humoral and CD4 ϩ T cell responses to CMV antigens of extracellular origin in very old individuals. Furthermore, we demonstrated a clear association between higher levels of antibodies and a greater degree of CD4 ϩ T cell differentiation in the elderly. The process of human immunosenescence, irrespective of its association with CMV, induces important changes in the T cell compartment. Although the two populations of CD8 ϩ and CD4 ϩ T cells undergo the same principal phenotypic shifts, the rates at which they occur or accumulate with age are very different. CD4
ϩ T cells are more resistant than CD8 ϩ T cells to phenotypic and functional changes with aging, probably because they have important regulatory roles and need to be subjected to strict control mechanisms (27) . In this way, there was an association between titers of anti-CMV antibodies and the CD4 ϩ T cell phenotype in elderly but not in young individuals. This might be explained by the different levels of antibodies in the two age groups, but when we compared elderly and young individuals with equal levels of anti-CMV antibodies, we found that, as expected, the differences were not explained solely by anti-CMV antibody titers. Nevertheless, the changes were more pronounced in CD4
ϩ than in CD8 ϩ T cells in the elderly, and there were substantial differences with young individuals with increasing antibody titers. The accumulation of highly differentiated cells may not be the only reason for the changes in T cell phenotype, and the impaired ability to replenish the pool of naïve T cells in elderly individuals also contributes to this. In humans, a dramatic drop in the absolute cell count of recent thymic emigrants with age is evident (28) . Despite this thymic degeneration, clinical lymphopenia is rare in elderly people and the number of circulating T cells is maintained over the life span, probably due to the increase in highly differentiated memory cells. Accordingly, we found that higher anti-CMV antibody titers were correlated with lower absolute counts of naïve and more highly differentiated T cells. However, there was no correlation with the total T lymphocyte count. Experienced T lymphocytes may fill the immunological space and homeostatic mechanisms block the generation of new naïve cells to maintain the numbers of peripheral T lymphocytes. These mechanisms make it difficult to preserve the T cell repertoire diversity that combats new pathogens as well as the host's ability to mount vigorous recall responses to recurrent infections (11) . Indeed, the loss of functionality with increasing differentiation and the reduction in naïve cells may be responsible for the suppression of immunity to other viruses and the impaired response to influenza vaccination reported for elderly donors with CMV infection (29) . In this way, an insufficient antibody response following influenza vaccination in elderly individuals has also been linked to a high frequency of CD8 ϩ CD28 null T cells (22) . In our study, both CMV seropositivity and the titer of anti-CMV antibodies corrected by age and CD8 ϩ CD28 null T cells were independently as- sociated with the antibody response to influenza virus vaccination. The impaired response to new antigens may be considered a marker of CMV infection-related immunosuppression, which has other possible consequences. CMV seropositivity is strongly associated with an IRP that is known to predict 2-year mortality in a population-based sample of Swedish octogenarians (9) . The IRP may be summarized by the presence of expanded populations of CD8 ϩ CD28 null memory T cells and an inverted CD4/CD8 ratio (30) . Recently, two studies have reported that not only the CMV infection but also the titer of CMV-specific antibodies is crucial for determining the risk of increased mortality (31, 32) . Differences related to CMV seropositivity in our study were more striking in CD28 null T lymphocytes from elderly and young individuals, but only the CD4/CD8 ratio and the frequency of CD4 ϩ
CD28
null T cells were correlated with antibody titers, and again not in the case of CD8 ϩ CD28 null T cells of elderly individuals. The magnitude of CMV infection may be influenced by genetic factors in the host. In HIV infection and renal transplantation, the presence of HLA-DR7 has been correlated with an increased risk of infection and CMV disease and with poor immune responses to CMV (33, 34) . It has been postulated that defective control of infection in HLA-DR7 patients could lead to frequent virus reactivations, contributing to the clonal expansion of specific subsets of CD4 ϩ T cells restricted against a limited number of CMV antigens (35) . In our study, we found no association between titers of anti-CMV antibodies and the HLA-DR alleles of the elderly individuals. Moreover, we found no association with their TNF-␣ polymorphisms, even though TNF-␣ is considered to be a key mediator of CMV reactivation. In turn, TNF-␣, which is augmented by aging and CMV infection, induces CD28 expression loss and T cell differentiation (36) . Despite the high levels of anti-CMV antibodies and the high frequencies of CD28 null T cells, we found no association between CMV infection and TNF-␣ levels in the sera of elderly individuals. There was a significant correlation with the level of IL-15, another cytokine implicated in the loss of CD28 expression in CD8 ϩ T cells and an inducer of preferential proliferation and functional capabilities of CD4 ϩ CD28 null T cells (20, 37) .
In summary, our data show that levels of anti-CMV antibodies and CMV seropositivity are related to differentiation status and immunocompetence in the elderly. Elevated anti-CMV antibody titers could be a consequence rather than the cause of immunosenescence, but they may have value as a prognostic marker of the deterioration of immunological status and the risk of age-related diseases.
